Is BioVie Inc. (BIVI) a Buy, Sell, or Hold?
NASDAQ : BIVI
BioVie Inc.
$1.35 USD
-$0.69 (-33.82%)
- Volume
- 8.74M
- Average Volume
- 165.83K
- Market Capitalization
- $10.18M
- P/E Ratio
- -0.92
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.98
- Year Low
- $0.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.97
Company Overview
NASDAQ
Cuong Viet Do
Biotechnology
Healthcare
BIVI
13
US
USD
Liquidity Metrics
0.02
9.97
9.97
7.73
0.00
Sales & Valuation
-$
0.00
0.65
-0.50
-2.72
Profitability
-$12.12
-$17.54M
0.00%
0.00%
-101.09%
-113.71%
P/E Metrics
-0.92
0.00
0.00
Analyst Price Target & Rating
3/5
5 Analysts
%
Financial Health Scores
-27.67
1/9
$15.19M
$17.51M
$1.91M
-$19.94M
Key Metrics (TTM)
$2.58M
0.00
-0.13
9.97
-101.09%
-129.50%
-129.42%
-133.30%
-2564 days
Company Executives
| Name | Title |
|---|---|
| Joseph Palumbo | Executive Vice President of R&D and Chief Medical Officer |
| Penelope Markham | Senior Vice President of Liver Disease & Long COVID Programs |
| Denise Smith | Senior Vice President of Manufacturing & Development |
| Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary |
| Clarence N. Ahlem | Senior Vice President of Operations |
| Cuong Viet Do | President, Chief Executive Officer & Director |
| David Morse | Senior Vice President & Chief Regulatory Officer |
| Christopher L. Reading | Senior Vice President of Alzheimer's Disease Program |
Poll Results
No votes yet today — be the first to share your view!
About BioVie Inc. (NASDAQ:BIVI) Stock
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company ... adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Apple App Store revenue ticks up despite falling downloads
2026-08-06 11:43:00
Apple Inc (NASDAQ:AAPL, XETRA:APC) App Store revenue rose 0.6% year-over-year in the first 35 days of its fiscal fourth quarter to $3.4 billion, up from...
Uber price target lowered by Bank of America despite higher earnings outlook
2026-08-06 11:33:00
Uber Technologies Inc (NYSE:UBER, XETRA:UT8) saw its price target lowered to $101 from $103 by Bank of America, which maintained a ‘Buy’ rating following...
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
2026-08-06 09:05:24
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo. The SUNRISE-PD trial was a multicenter, randomized, double-blind, placebo-controlled study in patients with early-stage Parkinson's disease who had not previously been treated with carbidopa/levodopa.
2026-08-06 07:30:00
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures. Bezisterim treatment appeared to have a beneficial impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro- and systemic-inflammation.
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-06-05 15:31:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
2026-06-02 20:52:07
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie: Long COVID trial fully enrolled – ICYMI
2026-05-29 16:31:33
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
BioVie: Long COVID trial fully enrolled – ICYMI
2026-05-29 12:30:00
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment,...
Frequently Asked Questions
-
What is the current BioVie Inc. (BIVI) stock price?
-
BioVie Inc.(NASDAQ:BIVI) stock price is $1.35 in the last trading session. During the trading session, BIVI stock reached the peak price of $3.98 while $0.82 was the lowest point it dropped to. The percentage change in BIVI stock occurred in the recent session was --33.82% while the dollar amount for the price change in BIVI stock was -$0.69.
-
BIVI's industry and sector of operation?
-
The NASDAQ listed BIVI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIVI?
-
Joseph Palumbo | Executive Vice President of R&D and Chief Medical Officer
Penelope Markham | Senior Vice President of Liver Disease & Long COVID Programs
Denise Smith | Senior Vice President of Manufacturing & Development
Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary
Clarence N. Ahlem | Senior Vice President of Operations -
How many employees does BIVI have?
-
Number of BIVI employees currently stands at 13. BIVI operates from 680 West Nye Lane, Carson City, NV 89703, US.
-
Link for BIVI official website?
-
Official Website of BIVI is: https://bioviepharma.com
-
How do I contact BIVI?
-
BIVI could be contacted at phone #775 888 3162 and can also be accessed through its website. BIVI operates from 680 West Nye Lane, Carson City, NV 89703, US.
-
How many shares of BIVI are traded daily?
-
The average number of BIVI shares traded daily for last 3 months was 165.83K.
-
What is the market cap of BIVI currently?
-
The market value of BIVI currently stands at $10.18M with its latest stock price at $1.35